1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
I-Tech AB

I-Tech AB

ITECH.ST
I-Tech ABSE flagStockholm Stock Exchange
69.00
SEK
-1.00
- -
827.85MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.43
1.5
2.43
3.83
4.44
4.44
7.02
10.15
15.18
- -
15.7
Basic EPS, GAAP
-0.6
-0.71
-1.15
0.71
-0.4
-0.22
0.89
1.7
3.3
- -
3.32
Free Cash Flow per Basic Share
-0.36
-0.64
-1.04
-0.47
0.4
-0.2
1.68
2.95
2.96
- -
3.82
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
1.51
- -
1.75
Book Value per Share
-0.09
-3.02
-3.5
-2.79
-3.19
-3.35
-2.42
-0.72
1.06
- -
3.48
Tangible Book Value per Share
-0.06
0.15
2.91
4.24
4.53
4.99
6.59
8.91
11.39
- -
11.71
Basic Weighted Avg Shares
12
12
12
12
12
12
12
12
12
- -
12
Sales/Revenue/Turnover
17
18
29
46
53
53
84
121
179
168
187
Operating Margin (%)
-40.13
-45.59
-49.61
-17.73
-11.37
-9.4
12.06
18.1
24.08
23.52
25.98
Depreciation Expense
1
1
7
8
9
8
8
8
8
8
8
Net Income, GAAP
-7
-8
-14
8
-5
-3
11
20
39
33
40
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
20.92
20.75
20.67
20.66
20.74
Profit Margin (%)
-41.96
-47.16
-47.46
18.49
-9.1
-5.01
12.7
16.72
21.74
19.74
21.13
Working Capital
12
15
46
43
41
44
63
94
132
157
137
LT Debt
- -
13
11
9
4
2
- -
- -
- -
- -
- -
Total Equity
35
37
103
111
107
105
116
136
157
174
159
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
7
13.61
23.27
18.33
26.21
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-34.22
-115.32
1,929.01
176.98
98.8
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
173.09
96.2

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
691
1,006
1,191

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
148
170
157
Cash, Cash Equivalents & STI
100
126
113
Accounts Receivable, Net
27
37
36
Inventories
4
7
9
Total Current Liabilities
16
22
20
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
10.55%
10.8%
Free Cash Flow
- -
-183.64%
84.12%
Net Income, GAAP
- -
-75.47%
-14.92%
Sales/Revenue/Turnover
- -
28.99%
-6.32%
Total Cash Common Dividend
- -
- -
16.67%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38
43
41
58
179
2025
57
32
39
- -
168
2026
53
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.69
0.73
0.65
1.2
3.3
2025
1.16
0.3
0.53
- -
- -
2026
1.29
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1.5
- -
- -
1.51
2025
- -
1.75
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Markus Jönsson
Full Time Employees
11
Sector
Healthcare
Industry
Biotechnology
Address
Pepparedsleden 1 Mölndal Sweden 431 83
IPO Date
May 28, 2018
Website
i-tech.se
Similar Companies
America Great Health (AAGH)
BridgeBio Pharma, Inc. (BBIO)
Pyxis Oncology, Inc. (PYXS)
Newron Pharmaceuticals S.p.A. (NWRN.SW)
Faron Pharmaceuticals Oy (FPHAF)
Emergent BioSolutions Inc. (EBS)
Business
I-Tech AB (publ) (Nasdaq First North Growth Market: ITECH), a Sweden-based biotechnology company founded in 1990 and headquartered in Mölndal, develops, markets and sells Selektope, an organic, metal-free biocide serving as a key performance ingredient in marine antifouling coatings; the product targets barnacle larvae through a unique pharmacological mode of action that repels settlement on ship hulls at low concentrations of 0.1% w/w, thereby reducing fuel consumption, emissions and operational costs for vessel operators worldwide. Selektope integrates into antifouling paints for both newbuild vessels and dry-dockings, serving the cleantech sector and global marine paint industry through a scalable B2B model that outsources production to contract manufacturers while focusing internally on sales, R&D and regulatory approvals. The company operates internationally with expanding geographic reach supported by approvals in key markets and supplies major paint manufacturers. In November 2025, I-Tech signed a Memorandum of Understanding with Guangdong Havey Advanced Materials Technology Co., Ltd. to advance collaborative R&D on next-generation antifouling materials, including Selektope combined with biodegradable resin binders; the partnership, building on joint activities since 2024, explores a potential joint venture to commercialize sustainable coating ingredients that enhance performance and reduce environmental impact such as VOC emissions. Recent years also feature supply agreements with two new global paint companies in 2024 alongside nearly 50% year-over-year sales growth, a strong Q1 2025 performance with net sales up approximately 50% year-over-year, and accelerated business development with additional customer product launches expected in 2025.